What is CJC-1295 (Without DAC)

CJC-1295 (Without DAC) is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) studied in research for its ability to stimulate the pituitary gland to secrete endogenous growth hormone. It is intended exclusively for research use.

Regarding its chemical identity, CJC-1295 has a molecular formula of C152H252N44O42 and a molecular weight of 3367.9 g/mol. Its reported canonical sequence is Tyr-d-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include CJC-1295.

Product for research use.

Mechanism of action of CJC-1295

CJC-1295 without DAC acts as a potent agonist of the GHRH receptor. By binding to these receptors in the anterior pituitary, it triggers a pulsatile release of Growth Hormone (GH) and subsequently Insulin-like Growth Factor 1 (IGF-1), leading to increased protein synthesis and lipolysis.

Pharmacokinetics and pharmacodynamics of CJC-1295

This version lacks the Drug Affinity Complex (DAC), resulting in a plasma half-life of approximately 30 minutes. This short half-life mimics the natural physiological pulsatile release of GH, as opposed to the continuous elevation seen with the DAC-bound version.

Scientific evidence on CJC-1295

The available evidence on CJC-1295 is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Extensively studied in models of growth hormone deficiency, muscle wasting, and anti-aging. It has been shown to increase IGF-1 levels significantly in animal models without negatively impacting natural pulsatile GH release.

CJC-1295 applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

CJC-1295 protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for CJC-1295, so no trial schemes or quantities are specified.

The presentations of this product (5MG and 10MG variations (CSV unspecified exact per vial, base title)) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of CJC-1295

As a general guideline for laboratory handling, lyophilized peptides such as CJC-1295 are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 5MG and 10MG variations (CSV unspecified exact per vial, base title) contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

CJC-1295 Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented CJC-1295 security profile

The documented safety information in open sources for CJC-1295 is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Increased GH secretion can theoretically lead to water retention, joint pain, and altered insulin sensitivity. As an unregulated research chemical, long-term safety profiles regarding its impact on pituitary function are largely inconclusive.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

CJC-1295 in a comparative context

Compared to native GHRH (which has a half-life of minutes), CJC-1295 without DAC is modified (D-Ala2, Gln8, Ala15, Leu27) to resist DPP-IV enzymatic degradation. Compared to CJC-1295 with DAC, it preserves the natural pulsatile release of GH.

History and development of CJC-1295

Developed by ConjuChem Biotechnologies to treat lipodystrophy and growth hormone deficiencies. While the DAC version saw more clinical development, the non-DAC version (often confused with Modified GRF 1-29) became widely used in research settings to study episodic GH release.